AnaptysBio, Inc. ANAB Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Research And Development Expense Excluding Acquired In Process Cost by Business | |||||
| Biopharma Company | $139.61M-8.4% | $152.35M+68.8% | $90.26M— | —— | |
| Royalty Management Company | -$3.64M-132% | $11.5M-72.6% | $42.03M— | —— | |
| Revenue by Product | |||||
| Anaptys Bio Generated Anti PD1Jemperli Dostarlimab | $258M— | —— | $0-100% | $93M+55.0% | |
| License | $9.6M— | —— | —— | —— | |
| General And Administrative Expense by Product | |||||
| External Expenses | $17.94M+78.8% | $10.03M+21.0% | $8.29M+13.9% | $7.29M— | |
| Internal Expenses | $32.79M+1.4% | $32.36M-3.9% | $33.65M+14.6% | $29.36M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AnaptysBio, Inc. break its business down?
- AnaptysBio, Inc. (ANAB) reports revenue by business across 2 parts — Biopharma Company and Royalty Management Company. Each is extracted from the segment footnotes and tracked over time.
- Where does AnaptysBio, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AnaptysBio, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.